Aim: this article describes the use of chloroquine as an antimalarial agent with potential antivirotic indications for COVID-19 infections. Methods: On line searches and gray literature have been used in the construction of this articles, whose database include PUBMED Central, BVS/BIREME, Web of Science, Science Direct, Higher Level Personnel Improvement Coordinator (CAPES), Periodic Door (Portal de Periódicos da CAPES, The Cochrane Library and PROSPERO). Results: chloroquine and hydroxychloroquine has shown appropriate clinical reports when associated with the antibiotic Azithromycin. It has been authorized for the clinical treatment of grave acute forms of COVID infections by countries like Brazil and USA. Conclusions: Chloroquine seems to have potential antivirotic properties that may be useful in the treatment of the grave acute forms of COVID-19 associated with Azithromycin. Nevertheless, Its indication must include ECG monitoring due to the risk of cardiac QT prolongation able to cause sudden deaths.

Objective: to accomplish a literature review to research the clinical characteristics of azythromycin, and its indications and associations for SARS-CoV-2 infections.  Methodology: Electronic searches were carried out on PUBMED Central, BVS/BIREME, Web of Science and The Cochrane Library with the aid of key-words. Results: Azithromycin is a secure antibiotic belonging to the macrolide class, effective for a vast number of infections, especially respiratory diseases. It seems to have viral indirect activity due to its being capable of altering the cell machinery, including mitochondrias, for changing the normal functioning of mitochondrial ribosomes. Conclusion: It is uncertain whether azithromycin is eligible for the treatment of virus infections in general and especially for COVID-19. Its combination with hydroxychloroquine, however, should be better researched in order to answer if it can be applied as a clinical approach for this matter.